Cancer Detecting mRNA Technology and AI Platform Receives FDA Breakthrough Designation

Bellevue-based Viome announced its proprietary mRNA analysis technology combined with its next-generation AI platform had been designated a Breakthrough Device by the Food and Drug Administration (FDA) for early detection of oral cancer and throat cancer.

Making saliva the new liquid biopsy, Viome analyzes samples for the presence of Oral Squamous Cell Carcinoma and Oropharyngeal Cancer.

Viome has employed unique mRNA analysis technology and breakthrough machine learning techniques to accurately discover the interactions between microbial activities and human gene expression in the progression of these cancers.

Founded in Washington during 2016, Viome has become a global healthcare company, developing precision nutrition, precision drugs, and precision vaccines to help people live a disease-free life.